Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$7.6 million.

  • Mangoceuticals' Income from Continuing Operations fell 28099.71% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.8 million, marking a year-over-year decrease of 11253.74%. This contributed to the annual value of -$8.7 million for FY2024, which is 548.38% up from last year.
  • Per Mangoceuticals' latest filing, its Income from Continuing Operations stood at -$7.6 million for Q3 2025, which was down 28099.71% from -$5.4 million recorded in Q2 2025.
  • In the past 5 years, Mangoceuticals' Income from Continuing Operations registered a high of -$1.8 million during Q3 2023, and its lowest value of -$7.6 million during Q3 2025.
  • Its 3-year average for Income from Continuing Operations is -$3.3 million, with a median of -$2.4 million in 2024.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 2412.15% in 2024, then plummeted by 28099.71% in 2025.
  • Over the past 3 years, Mangoceuticals' Income from Continuing Operations (Quarter) stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then crashed by 290.99% to -$7.6 million in 2025.
  • Its last three reported values are -$7.6 million in Q3 2025, -$5.4 million for Q2 2025, and -$4.8 million during Q1 2025.